# Patient-Trial Match Report

*Generated: 2026-01-05 06:56:57*

## Patient Profile

- **Age**: 45
- **Sex**: Female
- **Cancer Type**: melanoma
- **Biomarkers**: BRAF V600E

**Clinical Description**:
> 45-year-old female with metastatic cutaneous melanoma, BRAF V600E mutated. Primary on left lower extremity (Breslow 2.8mm) resected 2023. Developed lung and subcutaneous metastases 8 months later. First-line dabrafenib/trametinib achieved partial response but progressed at 14 months. Second-line nivolumab/ipilimumab combination - mixed response, eventually progressed with new splenic lesions. Currently well-appearing with good functional status. LDH elevated (312). Looking for novel combinations or emerging targets. No brain mets on most recent MRI.

- **Location Preference**: United States

## Search Summary

- **Search terms used**: 11
- **Total trials evaluated**: 100
- **Excluded by fast filter**: 39
- **LLM scored**: 61

## ðŸŸ¢ HIGH Likelihood (22 trials)

### [NCT05136196](https://clinicaltrials.gov/study/NCT05136196)

**Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study**

- **Sponsor**: National Cancer Institute (NCI)
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age: 45
- Sex: female
- Cancer type: metastatic cutaneous melanoma
- Biomarkers: BRAF V600E
- ECOG status: 0
- PD-L1: 60%
- No brain metastases

**Assessment:**
> The patient's cancer type matches the trial focus on advanced melanoma, and she is a previously treated patient which aligns with the trial's acceptance of relapsed or refractory cases.

---

### [NCT05779423](https://clinicaltrials.gov/study/NCT05779423)

**A Phase II Study of Core Needle Biopsy and Cryoablation of an Enlarging Tumor in Patients With Advanced Melanoma Receiving Post-progression Dual Immune Checkpoint Inhibitor Therapy**

- **Sponsor**: Massachusetts General Hospital
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has metastatic melanoma, which matches the trial conditions studied (metastatic melanoma, skin cancer).
- Patient has progressed on nivolumab, which is listed as a previous therapy and meets the criteria for progression on immune checkpoint inhibitors.
- Patient has an ECOG performance status of 0, which is eligible for dual checkpoint inhibition.
- Patient has a tumor amenable to cryoablation based on the description of metastases.
- Patient has measurable disease (lung and subcutaneous metastases).
- Patient's age is 45, which is above the minimum age requirement of 18.

**? Uncertainties:**
- Organ function lab results (leukocytes, ANC, platelets, bilirubin, AST/ALT, CrCL) are not provided.
- Unknown if the tumor has had previous radiation therapy, which could impact eligibility for cryoablation.

**Assessment:**
> The patient's cancer type (metastatic melanoma) matches the targeted condition of the trial and they have a history of progression after previous immune checkpoint inhibitor therapies. Their ECOG status and age also meet the trial criteria. There are minor uncertainties regarding organ function lab results and any prior radiation effects, but overall, the patient likely qualifies.

---

### [NCT06771544](https://clinicaltrials.gov/study/NCT06771544)

**Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma**

- **Sponsor**: University of California, Irvine
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has metastatic cutaneous melanoma, which matches the trial's condition studied.
- ECOG status is 0, meeting the performance status requirement.
- Patient has measurable disease with lung and subcutaneous metastases.
- PD-L1 expression is 60%, exceeding the trial's requirement of having progressed on prior PD-1 treatment.

**? Uncertainties:**
- No specific lab results provided to confirm organ function such as hemoglobin levels, platelets, ANC, creatinine clearance, AST, ALT, and bilirubin levels.

**Assessment:**
> The patient's cancer type aligns with the trial's focus on melanoma and the treatment line requirements match as the patient is refractory to prior therapies. The ECOG performance status meets the specified inclusion criteria. However, the lack of detailed organ function lab results leads to some uncertainties.

---

### [NCT06708455](https://clinicaltrials.gov/study/NCT06708455)

**Phase 2 Trial of Autologous Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy of PD-(L)1 Resistant Malignant Melanoma**

- **Sponsor**: Rapa Therapeutics LLC
- **Phase**: Phase 2
- **Status**: Not yet recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age: 45 (Eligible as age is â‰¥ 18)
- ECOG status: 0 (Eligible)
- Cancer type: melanoma (matches the trial focus)
- Biomarker: BRAF V600E (matches eligibility for prior BRAF therapy)
- Prior therapies: Received anti-PD-(L)1 therapy (nivolumab/ipilimumab) which demonstrates refractory status
- No brain metastases (eligible as there are none)
- PD-L1: 60% (meets the condition for PD-L1 positive melanoma)
- Currently well-appearing with good functional status

**? Uncertainties:**
- Elevated LDH (312) - unsure how it affects eligibility, but it could represent clinical concern
- Absolute lymphocyte count (ALC) is unknown - needed to evaluate eligibility for cell manufacturing
- Hematologic parameters (ANC, Platelet count, Hemoglobin) are unknown and need verification
- Creatinine clearance (calculated creatinine clearance is unknown)
- Ejection fraction (EF) status is unknown

**Assessment:**
> The patient's cancer type is melanoma, which is the focus of the trial. She has previously received anti-PD-1 therapy and has a BRAF mutation, making her a candidate for this treatment. Minor uncertainties exist mostly related to lab results that are not provided but do not critically affect the assessment of her eligibility.

---

### [NCT04119024](https://clinicaltrials.gov/study/NCT04119024)

**Phase I Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma and Other Solid Tumors**

- **Sponsor**: Anusha Kalbasi
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age: 45 (between 18-75 years old)
- ECOG status: 0 (acceptable performance status)
- Cancer type: metastatic melanoma (matches trial indication)
- Prior therapies: progressive after required systemic therapy including immune checkpoint and BRAF inhibitors

**? Uncertainties:**
- Confirmed IL13Ralpha2 tumor expression status
- Absolute neutrophil count (ANC) status
- Platelet count status
- Hemoglobin level status
- AST and ALT levels status
- Total bilirubin level status
- Creatinine level status
- LDH level significance in relation to eligibility

**Assessment:**
> The patient has metastatic melanoma which aligns perfectly with the trial indication. The patient is within the age limit, has an acceptable ECOG performance status, and has progressed through the required systemic treatments including immune checkpoint inhibitors and BRAF/MEK inhibitors. However, the specific laboratory values required for eligibility are not provided, which introduces some uncertainty.

---

### [NCT06608511](https://clinicaltrials.gov/study/NCT06608511)

**Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers**

- **Sponsor**: University of Wisconsin, Madison
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Confirmed diagnosis of melanoma
- ECOG status 0
- Age 45

**Assessment:**
> The patient's cancer type matches the trial conditions as she has a confirmed diagnosis of melanoma. The trial is observational, allowing for previously treated patients, and her age and ECOG status are within acceptable ranges.

---

### [NCT06946225](https://clinicaltrials.gov/study/NCT06946225)

**A First-in-human, Open-label Trial to Evaluate the Combination of ACTengineÂ® IMA203 With mRNA-4203 in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma or Synovial Sarcoma Patients (ACTengineÂ® IMA203-102)**

- **Sponsor**: Immatics US, Inc.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Pathologically confirmed and documented cutaneous melanoma
- ECOG status 0
- PD-L1 60% (greater than 50%)
- Prior therapies included a PD-1 inhibitor (nivolumab)

**? Uncertainties:**
- HLA-A*02:01 status (unknown)
- Adequate organ function (not provided)
- LDH threshold (elevated LDH of 312 without threshold context)

**Assessment:**
> The patient's cancer type of metastatic cutaneous melanoma aligns with the trial's indication. The patient has a history of prior systemic therapy, which meets the requirement for previously treated patients. The ECOG status is acceptable and PD-L1 is sufficient. However, uncertainties regarding HLA-A*02:01 status and specific organ function criteria slightly lower confidence.

---

### [NCT04291105](https://clinicaltrials.gov/study/NCT04291105)

**Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Patients With Select Solid Tumors**

- **Sponsor**: Vyriad, Inc.
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has histologically confirmed diagnosis of advanced metastatic cutaneous melanoma.
- PD-L1 status is 60%, which is greater than the required 1%.
- ECOG status is 0, which meets the performance criteria.
- The patient has shown PD on anti-PD-1 therapy (nivolumab) after prior treatment.

**? Uncertainties:**
- Organ function lab values are not provided to confirm adequacy.
- No details on availability of alternative curative therapeutic options.

**Assessment:**
> The patient has a confirmed diagnosis of melanoma, meets the treatment requirements having progressed on anti-PD-1 therapy, and has an acceptable ECOG performance status. There are minor uncertainties related to organ function and alternative options, but these do not affect the overall eligibility assessment.

---

### [NCT05503797](https://clinicaltrials.gov/study/NCT05503797)

**A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations**

- **Sponsor**: Fore Biotherapeutics
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has a histologic diagnosis of melanoma, which is a solid tumor studied in the trial.
- Patient has a documented BRAF V600E mutation.
- Patient is 45 years old, which falls within the acceptable age range (â‰¥10 years).
- ECOG status is 0, indicating good functional status.
- Patient has metastatic disease and has received all available standard therapy.

**? Uncertainties:**
- LDH level is elevated; it is unclear if this affects eligibility.
- No details on organ function labs are provided.

**Assessment:**
> The patient's melanoma diagnosis aligns with the trial's focus on cancers harboring BRAF alterations. The patient meets the age and ECOG status criteria, has a BRAF V600E mutation, and has received prior standard therapies, indicating she may qualify for the trial.

---

### [NCT06090266](https://clinicaltrials.gov/study/NCT06090266)

**A Phase 1/2 Study of OR502 Alone and in Combination With Other Anti-cancer Agents in Subjects With Advanced Malignancies**

- **Sponsor**: OncoResponse, Inc.
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has a histological diagnosis of cutaneous melanoma with progressive metastatic disease.
- Patient has an ECOG status of 0.
- Patient has no brain metastases.
- Patient has measurable disease.
- Patient is 45 years old and signed the informed consent.

**? Uncertainties:**
- Adequate organ function labs are not provided.

**Assessment:**
> The patient's cancer type (melanoma) aligns with the trial's indication, and she is previously treated, which fits the trial's criteria for prior therapies. The ECOG status and absence of brain metastases further support eligibility, but specifics about organ function are unclear.

---

### [NCT06265285](https://clinicaltrials.gov/study/NCT06265285)

**Pilot Single-Arm, Pragmatic Trial of In-Home Versus In-Clinic Subcutaneous Nivolumab Administration Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program**

- **Sponsor**: Mayo Clinic
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age: 45
- Sex: female
- Cancer type: metastatic cutaneous melanoma
- Biomarkers: BRAF V600E
- ECOG status: 0
- PD-L1: 60%
- No brain metastases

**? Uncertainties:**
- No specific organ function lab results provided (e.g., liver enzymes, bilirubin, renal function)
- Location specified as United States but nearby clinic distance not verified

**Assessment:**
> The patient's cancer type is applicable to the trial as it includes metastatic cutaneous melanoma. The patient has been treated previously but is currently in need of a new treatment regimen, which aligns with the trial's focus on advanced or metastatic malignancies (unresectable or metastatic cutaneous melanoma is explicitly included). The patient meets other supportive factors, but missing lab results and proximity to clinic introduce minor uncertainties.

---

### [NCT06975293](https://clinicaltrials.gov/study/NCT06975293)

**Open-label, Non-randomized, Multi-cohort, Phase 1b/2 Trial Investigating the Safety, Tolerability, and Antitumor Activity of STC-15 (a METTL3 Inhibitor) as a Part of Combination Therapy With Toripalimab in Participants With Selected Advanced Cancers**

- **Sponsor**: STORM Therapeutics LTD
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Cancer type: melanoma matches the trial's condition studied.
- ECOG status is 0, which is acceptable for the trial.
- The patient has a prior anti-PD-1 treatment (nivolumab), fulfilling melanoma inclusion criteria.

**? Uncertainties:**
- Radiological assessment of progression on the prior therapy documentation is not explicitly stated.

**Assessment:**
> The patient's cancer type (melanoma) matches the trial's focus, and she has the required treatment history including anti-PD-1 therapy. Although there is an uncertainty regarding the documented radiologic assessment, overall the eligibility criteria are met.

---

### [NCT02012699](https://clinicaltrials.gov/study/NCT02012699)

**Integrated Cancer Repository for Cancer Research**

- **Sponsor**: University of Nebraska
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Diagnosis/history of cancer: melanoma
- Age: 45
- ECOG status: 0
- PD-L1: 60%
- No brain metastases

**Assessment:**
> The patient's cancer type (melanoma) matches the trial conditions studied. The patient is previously treated, which is acceptable, and meets the age and ECOG criteria. There are no exclusionary factors present.

---

### [NCT05538130](https://clinicaltrials.gov/study/NCT05538130)

**A PHASE 1A/B OPEN-LABEL MASTER STUDY OF PF-07799544 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS**

- **Sponsor**: Pfizer
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Diagnosis of advanced/metastatic melanoma
- Patient has BRAF V600E mutation
- Measurable disease by RECIST version 1.1
- ECOG status of 0
- Patient has progressive disease after prior treatments

**? Uncertainties:**
- LDH level could be an uncertainty for organ function eligibility

**Assessment:**
> The patient's cancer type matches the trial's eligibility criteria for melanoma, and the patient has the required BRAF V600E mutation, along with measurable disease and an ECOG status of 0. The treatment line is appropriate as the patient has previously treated melanoma. The only uncertainty is the LDH level, which could affect organ function eligibility.

---

### [NCT05225428](https://clinicaltrials.gov/study/NCT05225428)

**Video Education With Result Dependent dIsclosure**

- **Sponsor**: Dana-Farber Cancer Institute
- **Phase**: Not Applicable
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age â‰¥ 18 years
- Current diagnosis of melanoma
- Ability to understand spoken or written English
- ECOG status 0

**? Uncertainties:**
- No information on prior cancer genetic testing
- No information on prior germline genetic testing
- No information regarding pregnancy or incarceration status
- LDH levels not explicitly stated if it affects eligibility

**Assessment:**
> The patient's diagnosis of metastatic cutaneous melanoma matches the trial's studied conditions. The patient is over 18 years old and has an ECOG status of 0, which supports their eligibility. There are some uncertainties regarding prior cancer genetic testing and potential active conditions, but these do not significantly affect the overall eligibility assessment.

---

### [NCT05746897](https://clinicaltrials.gov/study/NCT05746897)

**A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of NM1F as Monotherapy and in Combination With Pembrolizumab in Subjects With Locally Advanced/Metastatic Solid Tumors**

- **Sponsor**: Hefei TG ImmunoPharma Co., Ltd.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Cancer type is melanoma which is listed in the conditions studied
- ECOG status is 0
- Patient has at least 1 evaluable lesion
- Patient has a life expectancy â‰¥ 3 months
- Patient has sufficient baseline organ function and laboratory data (inferred from 'well-appearing')

**? Uncertainties:**
- Specific organ function and laboratory values not provided but are needed for confirming eligibility
- Confirmation of negative serum pregnancy test within 7 days before treatment is required since the patient is female and of childbearing potential

**Assessment:**
> The patient's cancer type matches the trial conditions, and she is a previously treated patient which aligns with the trial's focus on subjects who have progressed despite standard therapies. The ECOG status indicates good functional status, which further supports eligibility.

---

### [NCT05076760](https://clinicaltrials.gov/study/NCT05076760)

**Phase I Study Evaluating MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors**

- **Sponsor**: Memgen, Inc.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Cancer type is melanoma, which is included in the trial conditions studied.
- Patient has previously received a BRAF inhibitor (dabrafenib) for BRAF V600E mutated melanoma.
- ECOG status is 0, which meets the trial's inclusion criteria of ECOG performance status of 0 or 1.
- Patient is 45 years old, which meets the adult requirement (age â‰¥ 18 years).
- Patient has measurable disease as indicated by active lung and subcutaneous metastases.

**âœ— Potential Conflicts:**
- Patient has received multiple prior treatments including dabrafenib, trametinib, nivolumab, and ipilimumab, which meets the requirement of having received more than one line of therapy.

**? Uncertainties:**
- Organ function labs are not provided, so clarity on adequacy of organ function cannot be confirmed.
- No specific details on the tumor lesion's accessibility for injection are provided.

**Assessment:**
> The patient's cancer type of melanoma matches the trial's indication, and they have received the required prior therapies, fulfilling trial criteria. Minor uncertainties remain regarding organ function and tumor accessibility.

---

### [NCT05520099](https://clinicaltrials.gov/study/NCT05520099)

**Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)**

- **Sponsor**: Elephas
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has cutaneous melanoma, which matches the trial's condition of studying skin cancer and cutaneous melanoma.
- Patient is 45 years old, meeting the age requirement (â‰¥ 18 years).
- ECOG status is 0, indicating good performance status, which is acceptable for trials.
- Patient has PD-L1 of 60%, which may align with eligibility for immunotherapy considerations.

**? Uncertainties:**
- LDH elevated (312) - not specified whether this is within acceptable limits for eligibility.
- Details of the biopsy procedure and patient's ability to undergo it are not explicitly confirmed.

**Assessment:**
> The patient's cancer type matches the trial's targeted conditions, and they meet age and ECOG criteria. There are minor uncertainties regarding organ function and biopsy eligibility, but no disqualifying factors are present.

---

### [NCT05859074](https://clinicaltrials.gov/study/NCT05859074)

**A First-In-Human Phase I, Open Label, Safety and Tolerability Study of Escalating Multiple Doses of Intratumoral MQ710, a Multi-Transgene Expressing Modified Vaccinia Virus Ankara-Based Virotherapy, Alone and in Combination With the Systemic Checkpoint Inhibitor Pembrolizumab in Solid Tumors**

- **Sponsor**: Memorial Sloan Kettering Cancer Center
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age: 45
- Sex: female
- Cancer type: melanoma
- Biomarkers: BRAF V600E
- ECOG status: 0
- No brain metastases
- PD-L1: 60%
- Prior therapies: dabrafenib, trametinib, nivolumab, ipilimumab - meets prior therapy criteria for melanoma
- Patient resides in the United States which is the country of the trial.

**? Uncertainties:**
- Adequate renal function details (Cr level not provided)
- Adequate hepatic function details (AST/ALT/bilirubin levels not provided)
- Adequate bone marrow and hematologic function details (platelets, ANC levels not provided)
- Measurable disease status not stated, requires confirmation
- No information on recent infections or bleeding history.

**Assessment:**
> The patient's cancer type (melanoma) matches the trial's indication for advanced melanoma. The patient has received prior therapies as required for enrollment. The ECOG status is acceptable, and there are no brain metastases. However, some organ function details and measurable disease status are uncertain, which leaves some room for interpretation but does not alter eligibility significantly.

---

### [NCT01776905](https://clinicaltrials.gov/study/NCT01776905)

**In Vivo Real-time Detection of Circulating Melanoma Cells**

- **Sponsor**: University of Arkansas
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 75%

**âœ“ Supporting Factors:**
- Age: 45
- Sex: female
- Cancer type: melanoma
- Biomarkers: PD-L1: 60%
- ECOG status: 0
- No brain metastases

**? Uncertainties:**
- No information about active infection or current medical/surgical conditions
- No information provided about whether the patient has signed an informed consent form
- No information provided on the ability to sit still for 90 minutes

**Assessment:**
> The patient's cancer type matches the trial's focus on melanoma. She is 45 years old and has an ECOG status of 0, meeting the age and performance status criteria. Although she has prior therapies, the trial has no specific restrictions on treatment history, which aligns with her status as a previously treated patient. There are minor uncertainties regarding specific medical conditions and logistical aspects of participation.

---

### [NCT06418204](https://clinicaltrials.gov/study/NCT06418204)

**Complementary Options for Symptom Management In Cancer (COSMIC): Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics**

- **Sponsor**: Wake Forest University Health Sciences
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 75%

**âœ“ Supporting Factors:**
- Cancer type is melanoma, which is being studied in the trial.
- Patient has PD-L1 expression of 60%, which qualifies for immune checkpoint inhibitor therapy.
- Patient resides in the United States.

**âœ— Potential Conflicts:**
- Patient has received multiple prior therapies, which may indicate she is not treatment-naive, but trial does not explicitly state treatment-naive requirement.

**? Uncertainties:**
- Potential threshold for what constitutes 'newly diagnosed' is unclear since the patient's status may depend on timing of treatment response post-progression.

**Assessment:**
> The patient's cancer type matches the trial indication for melanoma. Although the patient has had prior therapies, there is ambiguity regarding whether these disqualify her from the trial, as the trial description does not clearly state that it seeks treatment-naive patients. Hence, while there are uncertainties, the overall profile supports potential eligibility.

---

### [NCT04572451](https://clinicaltrials.gov/study/NCT04572451)

**Phase I Study Investigating the Safety of Stereotactic Body Radiotherapy (SBRT) With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma**

- **Sponsor**: Yana Najjar
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 70%

**âœ“ Supporting Factors:**
- Cancer type: melanoma matches the trial conditions
- ECOG status: 0 is acceptable
- PD-L1: 60% meets the threshold for anti-PD1 therapy
- No brain metastases documented
- Age: 45 is above 18 years

**âœ— Potential Conflicts:**
- Patient has previously received anti-PD1 therapy (nivolumab) which may conflict with the trial's focus on anti-PD1 refractory cases

**? Uncertainties:**
- Organ function lab results not provided to confirm normal organ function

**Assessment:**
> The patient's melanoma diagnosis aligns with the trial's focus. The patient has already been treated with PD-1, which creates a conflict with eligibility for anti-PD1 refractory cases; however, other eligibility criteria are met. Organ function details are missing, leaving some uncertainty.

---

## ðŸŸ¡ MEDIUM Likelihood (3 trials)

### [NCT05786924](https://clinicaltrials.gov/study/NCT05786924)

**A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies**

- **Sponsor**: Institut de Recherches Internationales Servier
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 65%

**âœ“ Supporting Factors:**
- Patient has melanoma which is a solid tumor.
- Patient has BRAF V600E mutation.

**âœ— Potential Conflicts:**
- Trial primarily targets NSCLC and not melanoma; thus does not fully match the disease indication.
- Patient has prior systemic therapies and the trial includes treatment-naive or previously treated indication ambiguity.

**? Uncertainties:**
- No information on specific organ function parameters.
- It is unclear if the trial explicitly accepts melanoma as an eligible solid tumor in the absence of NSCLC.

**Assessment:**
> The patient's cancer type partially aligns with the trial conditions as BRAF V600E mutation is specified, but melanoma is not the primary focus of the trial, which is for NSCLC and other specific malignancies. There are also uncertainties regarding treatment line and organ function, which affect overall eligibility assessment.

---

### [NCT02279004](https://clinicaltrials.gov/study/NCT02279004)

**A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care**

- **Sponsor**: Dana-Farber Cancer Institute
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 60%

**âœ“ Supporting Factors:**
- Patient has advanced melanoma with BRAF V600E mutation.
- ECOG status is 0.

**âœ— Potential Conflicts:**
- Patient has previously received multiple systemic therapies, whereas the trial offers specific cohorts for treatment-naive or patients with acquired resistance.

**? Uncertainties:**
- Whether patient has a plan for re-biopsy for resistance genotyping.

**Assessment:**
> The patient's disease type (melanoma) matches the trial's focus, particularly with the BRAF V600E mutation. However, the patient has had multiple prior therapies, which puts her into a different treatment line than what the trial specifies, which potentially limits eligibility. The presence of a plan for potential re-biopsy for resistance genotyping is also unclear.

---

### [NCT04370587](https://clinicaltrials.gov/study/NCT04370587)

**A Phase 1/2a, Open-Label, Dose Escalation and Expansion Study of the Safety and Tolerability of T3011 Administered Via Intratumoral Injection as a Single Agent and in Combination With Intravenous Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors**

- **Sponsor**: ImmVira Pharma Co. Ltd
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 50%

**âœ“ Supporting Factors:**
- Cancer type is melanoma, which is included in the trial conditions.
- ECOG status is 0, meeting the trial requirement.
- PD-L1 expression is 60%, which is above the threshold for some trials.

**âœ— Potential Conflicts:**
- Patient has received 4 prior therapies (dabrafenib, trametinib, nivolumab, ipilimumab) while the trial specifies no more than 3 prior regimens for advanced or metastatic disease.
- Requires confirmation if the patient has at least 1 tumor lesion accessible for IT injection of T3011.

**? Uncertainties:**
- Patient's current organ function tests are not provided, making eligibility uncertain.
- No information on the requirement for adequate contraception prior to study entry, while on study treatment, and for six months after the last dose.

**Assessment:**
> The patient's cancer type matches the trial's focus on melanoma; however, the patient has more than the allowed number of prior therapies, leading to a potential conflict. There are also several uncertainties regarding organ function and other requirements, putting the overall confidence at a medium level.

---

## ðŸŸ  LOW Likelihood (3 trials)

### [NCT03743298](https://clinicaltrials.gov/study/NCT03743298)

**Phase 1B Trial of AV-MEL-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Antigens) With Anti-PD-1 Checkpoint Inhibitors in Metastatic Melanoma**

- **Sponsor**: Aivita Biomedical, Inc.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 30%

**âœ“ Supporting Factors:**
- Age > 18
- ECOG status 0
- PD-L1 60%
- Metastatic melanoma diagnosis

**âœ— Potential Conflicts:**
- Patient has received multiple prior therapies (not treatment-naive)
- Karnofsky Performance Status (KPS) has not been explicitly provided

**? Uncertainties:**
- Presence of at least one metastatic lesion that is to be surgically removed is unclear
- Patient's KPS is unspecified (could be < 70)

**Assessment:**
> The patient's cancer type matches the trial's indication; however, the patient has received prior systemic therapies, making her ineligible if the trial is for treatment-naive patients. There are uncertainties due to lack of clarity on KPS and the resection of a metastatic lesion.

---

### [NCT05053555](https://clinicaltrials.gov/study/NCT05053555)

**High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies**

- **Sponsor**: M.D. Anderson Cancer Center
- **Phase**: Not Applicable
- **Status**: Recruiting
- **Confidence**: 25%

**âœ“ Supporting Factors:**
- Age is 45, which is above the required minimum of 18
- ECOG status is 0

**âœ— Potential Conflicts:**
- Patient has melanoma, but trial focuses on liver malignancies. This may conflict with their eligibility depending on the specific criteria defined for the inclusion of melanoma patients.

**? Uncertainties:**
- Specific details about liver lesions or metastases are not provided, making it unclear if the patient has up to five unresectable tumors that meet the size and proximity criteria.
- Missing lab results for total serum bilirubin, platelet count, and INR, which are crucial for determining eligibility.

**Assessment:**
> The patient has melanoma, but the trial is targeting liver malignancies, which raises significant eligibility concerns. The absence of specific details about liver lesions and lab results further adds to uncertainties. Overall, the mismatch in cancer type and missing critical information leads to a low confidence in eligibility.

---

### [NCT02339571](https://clinicaltrials.gov/study/NCT02339571)

**Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma**

- **Sponsor**: National Cancer Institute (NCI)
- **Phase**: Phase 2/Phase 3
- **Status**: Recruiting
- **Confidence**: 20%

**âœ“ Supporting Factors:**
- Age: 45
- Sex: female
- Cancer type: melanoma
- Biomarkers: BRAF V600E
- ECOG status: 0
- PD-L1: 60%
- No brain metastases

**âœ— Potential Conflicts:**
- Patient has received nivolumab and ipilimumab in prior therapies, trial excludes patients who have had anti-PD-1/PD-L1 or ipilimumab in the metastatic setting.

**? Uncertainties:**
- Location does not affect eligibility as the patient is from the United States, which is within the trial region.
- Blood work results for white blood count, ANC, platelet count, hemoglobin, serum creatinine, AST, ALT, alkaline phosphatase, total bilirubin, and LDH are not provided.

**Assessment:**
> Patient's cancer type matches the trial, but she has previously received anti-PD-1 and anti-CTLA-4 agents in the metastatic setting, which leads to exclusion from the trial. Other aspects of eligibility could not be verified without more information.

---

## Excluded (69 trials)

### Excluded by Fast Filter

| NCT ID | Reason |
|--------|--------|
| [NCT02332668](https://clinicaltrials.gov/study/NCT02332668) | Patient age 45 is above maximum age 17 |
| [NCT07068074](https://clinicaltrials.gov/study/NCT07068074) | Patient age 45 is below minimum age 75 |
| [NCT02670707](https://clinicaltrials.gov/study/NCT02670707) | Patient age 45 is above maximum age 21 |
| [NCT02693535](https://clinicaltrials.gov/study/NCT02693535) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT03138161](https://clinicaltrials.gov/study/NCT03138161) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT03803553](https://clinicaltrials.gov/study/NCT03803553) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT03899155](https://clinicaltrials.gov/study/NCT03899155) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT03997786](https://clinicaltrials.gov/study/NCT03997786) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04079179](https://clinicaltrials.gov/study/NCT04079179) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04130516](https://clinicaltrials.gov/study/NCT04130516) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04166409](https://clinicaltrials.gov/study/NCT04166409) | Patient age 45 is above maximum age 21 |
| [NCT04262466](https://clinicaltrials.gov/study/NCT04262466) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04852887](https://clinicaltrials.gov/study/NCT04852887) | Patient age 45 is below minimum age 50 |
| [NCT05009992](https://clinicaltrials.gov/study/NCT05009992) | Patient age 45 is above maximum age 39 |
| [NCT05040360](https://clinicaltrials.gov/study/NCT05040360) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05379985](https://clinicaltrials.gov/study/NCT05379985) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05584670](https://clinicaltrials.gov/study/NCT05584670) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05677490](https://clinicaltrials.gov/study/NCT05677490) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05828069](https://clinicaltrials.gov/study/NCT05828069) | Patient age 45 is below minimum age 180 |
| [NCT05844982](https://clinicaltrials.gov/study/NCT05844982) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| ... | *and 19 more* |

### Excluded by Eligibility Assessment

| NCT ID | Sponsor | Reason |
|--------|---------|--------|
| [NCT06194929](https://clinicaltrials.gov/study/NCT06194929) | University of Utah | Patient has melanoma but this trial exclusively studies brain metastases from cutaneous melanoma. The patient has no brain metastases. |
| [NCT06697301](https://clinicaltrials.gov/study/NCT06697301) | Eikon Therapeutics | Patient has prior systemic therapy for advanced melanoma (dabrafenib, trametinib, nivolumab, ipilimumab), but the trial is designed for treatment-naive patients. |
| [NCT04930783](https://clinicaltrials.gov/study/NCT04930783) | Dana-Farber Cancer I | Prior treatments include nivolumab and ipilimumab, which are forms of immunotherapy. The trial excludes prior immunotherapy for metastatic melanoma except for anti-CTLA-4. |
| [NCT04697576](https://clinicaltrials.gov/study/NCT04697576) | Carlo Contreras | Patient has prior systemic therapies (dabrafenib, trametinib, nivolumab, ipilimumab) which contradicts trial requirements for treatment-naive patients |
| [NCT06216938](https://clinicaltrials.gov/study/NCT06216938) | Yana Najjar | The trial requires patients with grossly visible residual tumor, or a positive deep or lateral margin on initial biopsy. The patient has a resected primary melanoma without mention of grossly visible residual tumor. |
| [NCT06599619](https://clinicaltrials.gov/study/NCT06599619) | John Kirkwood | Patient has a current documented history of melanoma but does not meet the inclusion criterion for having at least two atypical nevi of â‰¥ 4 mm diameter. |
| [NCT06488365](https://clinicaltrials.gov/study/NCT06488365) | Cytoastra | Patient has prior systemic therapy (dabrafenib, trametinib, nivolumab, ipilimumab) but the study does not specify if it allows previously treated patients. |
| [NCT04752826](https://clinicaltrials.gov/study/NCT04752826) | BioInvent Internatio | Patient has received multiple prior therapies, including anti-PD-1 therapy, which is not eligible for Part B of the trial where subjects with prior lines of treatment are not eligible. |
| [NCT05576896](https://clinicaltrials.gov/study/NCT05576896) | Northwestern Univers | Patient has melanoma, but the trial is focused on colorectal cancer. |
| [NCT06440850](https://clinicaltrials.gov/study/NCT06440850) | City of Hope Medical | Patient has previously received prior anti-BRAF treatment (dabrafenib) |
| [NCT06814496](https://clinicaltrials.gov/study/NCT06814496) | University of Arizon | Patient has melanoma which is listed among the conditions studied, but the trial specifically targets DLL3 expressing tumors. There is no indication that the patient's melanoma is DLL3+. |
| [NCT03042221](https://clinicaltrials.gov/study/NCT03042221) | University of Colora | Patient has prior systemic therapy for metastatic disease (dabrafenib, trametinib, nivolumab, ipilimumab) while the trial requires no prior systemic therapy for locally advanced or metastatic disease. |
| [NCT00068003](https://clinicaltrials.gov/study/NCT00068003) | National Cancer Inst | Prior therapies: patient has undergone prior treatments (dabrafenib, trametinib, nivolumab, ipilimumab) whereas the trial may require treatment-naive or first-line patients. |
| [NCT05868629](https://clinicaltrials.gov/study/NCT05868629) | Novartis Pharmaceuti | Trial excludes participants with melanoma. |
| [NCT06102902](https://clinicaltrials.gov/study/NCT06102902) | National Cancer Inst | Patient has melanoma (not colorectal adenocarcinoma) which does not match the trial indication. |
| [NCT06666790](https://clinicaltrials.gov/study/NCT06666790) | DermaSensor, Inc. | Patient has prior systemic therapies (dabrafenib, trametinib, nivolumab, ipilimumab) which conflict with potential eligibility as the trial does not specify acceptance of previously treated patients. |
| [NCT06919809](https://clinicaltrials.gov/study/NCT06919809) | McGuire Institute | Patient has metastatic cutaneous melanoma but the trial is studying wound healing after Mohs surgery for BCC, SCC, or melanoma in situ (MIS), which typically does not include metastatic conditions. |
| [NCT06190951](https://clinicaltrials.gov/study/NCT06190951) | Regeneron Pharmaceut | Patient has received prior systemic therapy (dabrafenib, trametinib, nivolumab, ipilimumab) while trial requires no prior systemic therapy for melanoma |
| [NCT01638676](https://clinicaltrials.gov/study/NCT01638676) | University of Louisv | Prior treatment with Vemurafenib - the trial excludes prior Vemurafenib treatment |
| [NCT04598009](https://clinicaltrials.gov/study/NCT04598009) | University of Califo | Patient has BRAF V600E mutation, but the trial is for patients with advanced KIT-mutant melanoma. |
| ... | ... | *and 10 more* |

## Search Terms Used

| Term | Source | Confidence |
|------|--------|------------|
| BRAF V600E | manual | 1.0 |
| BRAFV600E | manual | 0.9 |
| BRAF-V600E | manual | 0.9 |
| melanoma | manual | 1.0 |
| BRAF V600E melanoma | manual | 1.0 |
| BRAF V600E cutaneous melanoma | llm | 0.9 |
| BRAF V600E metastatic melanoma | llm | 0.9 |
| cutaneous melanoma | llm | 0.8 |
| metastatic melanoma | llm | 0.8 |
| BRAF V600E mutant | llm | 0.9 |
| BRAF V600E mutation | llm | 0.9 |

## Information That Would Improve Matches

The following patient data was not provided but would help refine eligibility assessment:

- **Organ function labs** (hematology, liver, renal) - required by all interventional trials
- **Measurable disease status** (per RECIST 1.1) - required for most therapeutic trials
